Screening for triazole resistance in clinically significant aspergillus species; report from Pakistan by Moin, Safia et al.
eCommons@AKU 
Department of Pathology and Laboratory 
Medicine Medical College, Pakistan 
5-11-2020 
Screening for triazole resistance in clinically significant 
aspergillus species; report from Pakistan 
Safia Moin 
Aga Khan University, safia.moin@aku.edu 
Joveria Farooqi 
Aga Khan University, joveria.farooqi@aku.edu 
Kausar Jabeen 
Aga Khan University, kausar.jabeen@aku.edu 
Sidra Laiq 
Aga Khan University, sidra.laiq@aku.edu 
Afia Zafar 
Aga Khan University, afia.zafar@aku.edu 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol 
 Part of the Pathology Commons 
Recommended Citation 
Moin, S., Farooqi, J., Jabeen, K., Laiq, S., Zafar, A. (2020). Screening for triazole resistance in clinically 
significant aspergillus species; report from Pakistan. Antimicrobial Resistance and Infection Control, 9(1), 
62. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1235 
RESEARCH Open Access
Screening for triazole resistance in clinically
significant Aspergillus species; report from
Pakistan
Safia Moin, Joveria Farooqi* , Kauser Jabeen, Sidra Laiq and Afia Zafar
Abstract
Background: Burden of aspergillosis is reported to be significant from developing countries including those in
South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung
diseases. There is concern for management of aspergillosis with the emergence of azole resistant Aspergillus species
in neighbouring countries in Central and South Asia.
Hence the aim of this study was to screen significant Aspergillus species isolates at the Microbiology Section of Aga
Khan Clinical Laboratories, Pakistan, for triazole resistance.
Methods: A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from
September 2016–May 2019. One hundred and fourteen, clinically significant Aspergillus isolates [A. fumigatus (38;
33.3%), A. flavus (64; 56.1%), A. niger (9; 7.9%) A. terreus (3; 2.6%)] were included. The clinical spectrum ranged from
invasive aspergillosis (IA) (n = 25; 21.9%), chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%), allergic
bronchopulmonary aspergillosis (ABPA) (n = 4; 3.5%), severe asthma with fungal sensitization (SAFS) (n = 4; 3.5%),
saprophytic tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by
antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were
tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method.
Results: All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested
isolates were found to be ≤1 ml/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates
from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required
to inhibit the growth of 90% organisms (MIC90) of itraconazole, voriconazole and posaconazole of the
representative Aspergillus isolates was 1 mg/L, 1 mg/L and 0.5 mg/L, respectively.
Conclusion: Triazole resistance could not be detected amongst clinical Aspergillus isolates from the South of
Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study
will set precedence for future periodic antifungal resistance surveillance in our region on Aspergillus isolates.
Keywords: Aspergillosis, Aspergullus flavus, Aspergullus fumigatus, Aspergullus Niger, Aspergullus terreus, Itraconazole,
Voriconazole and posaconazole
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Background
Aspergillus species have emerged as an important cause
of morbidity and mortality in the immunocompromised
patients with a wide spectrum of aspergillosis requiring
systemic antifungal therapy [1]. Invasive pulmonary as-
pergillosis (IPA) is a life threatening pneumonia character-
ized by lung parenchymal invasion with vascular erosion
and necrosis [2]. Furthermore, Aspergillus species also pro-
duce a wide range of chronic, saprophytic, and allergic con-
ditions. Chronic pulmonary aspergillosis (CPA) can be a
debilitating illness, progressing rapidly as in sub acute inva-
sive aspergillosis (SAIA) or more slowly as chronic cavitary
pulmonary aspergillosis (CCPA) and chronic fibrosing pul-
monary aspergillosis (CFPA). Thus the clinical spectrum of
aspergillosis requiring systemic therapy is very wide, ran-
ging from fulminant invasive disease in patients with no im-
mune defenses to slowly progressing fibrosing disease as
seen in CFPA and severe asthma with fungal sensitization
(SAFS) or allergic bronchopulmonary aspergillosis (ABPA).
Burden of IA and the other forms of aspergillosis have
been reported to be significant from developing coun-
tries including South Asia and South East Asia [3]. Due
to inadequate population based surveillance, the accur-
ate burden of fungal infection in Pakistan has not been
documented. However infections prevailing in our coun-
try project a high fungal burden and an estimate has
been drawn for the major fungal burden with the help of
data from neighboring countries like India [4].
Aspergillus fumigatus is the predominant etiological
agent isolated from IPA cases closely followed by As-
pergillus flavus in South Asia [5–8]. Long term tri-
azole therapy is recommended for the treatment of
IPA [9]. Management of IPA and the other forms of
aspergillosis has become challenging with the emer-
gence of azole resistance in Aspergillus species espe-
cially Aspergillus fumigatus [10]. Long-term azole
therapy and the unrestricted use of azole compounds
in the environment as fungicides in the agricultural
and horticultural industry have been identified as risk
factors for development of resistance [10]. Some of
the fungicides have a similar molecule structure to
the triazoles used in treatment and hence lead to
azole resistance. This is of great importance to an
agricultural country like Pakistan.
Due to the life threatening nature of these infections,
surveillance for resistance has become extremely import-
ant [1, 11]. Standard susceptibility testing method is
broth microdilution for molds according to the Euro-
pean Committee on Antibiotic Susceptibility Testing
(EUCAST) and Clinical and Laboratory Standards Insti-
tute (CLSI) [1]. This technique is technically challenging
and time consuming. Therefore the strategy adopted by
most clinical laboratories is to first screen Aspergillus
species for triazole resistance. The isolates that are
initially found to be resistant on screening are further
tested by the standard broth microdilution.
Hence the aim of this study was to screen significant
Aspergillus species isolates at the Microbiology Section
of Aga Khan Clinical Laboratories for triazole resistance.
This will set precedence for future periodic antifungal
resistance surveillance studies in our region on Aspergil-
lus isolates causing invasive disease, as well as other syn-
dromes requiring long term antifungal therapy.
Materials and methods
The aim of this study was to screen significant Aspergil-
lus species isolates. It was a prospective, descriptive
cross-sectional study conducted in the Aga Khan Uni-
versity Clinical Laboratories, Karachi, from September
2016 to May 2019.
Identification and susceptibility testing
Aspergillus species isolated from the clinical specimen
from patients with appropriate host factors and suffi-
cient clinical evidence consistent with the above men-
tioned clinical spectrum were included in the study.
They were assessed for their clinical significance using
EORTC 2008, AspICU, and the clinical spectrum of pul-
monary aspergillosis [12–17]. Non Aspergillus species
were excluded. The Aspergillus isolates were identified
based on the colony morphology and microscopic
morphology [18]. Inoculum was prepared according to
CLSI [19]. Briefly, the Aspergillus isolates were grown on
potato dextrose agar slants for 5 days at 35 °C or until
good sporulation was observed. The sporulating colonies
were covered with 1 mL of sterile 0.85% saline and the
colonies were gently probed with the tip of a transfer
pipette to prepare a suspension. The resulting mixture
of conidia, sporangiophores and hyphal fragments was
withdrawn and transferred to a sterile tube and after
allowing the heavy particles to settle for three to 5 min,
the upper homogenous suspension was transferred to
another sterile tube. The cap was tightened and the sus-
pension vortexed thoroughly for 15 s. The conidia or
sporangiophore suspension was adjusted to an optical
density (O.D.) at 530 nm that ranges from 0.09 to 0.13
for Aspergillus spp.
Screening for triazole resistance was performed by anti-
fungal agar screening method as described by Mortensen
et al [20] Itraconazole, voriconazole and posaconazole,
powders from the Sigma-Aldrich Company (St. Louis,
MO, USA) were used to prepare the agar screening plates.
Subsequently 50 μl was inoculated in each well of a four-
well petri plate containing Roswell Park Memorial Insti-
tute (RPMI) 1640 agar with 2% glucose supplemented
with itraconazole (4mg/L), voriconazole (1mg/L), and
posaconazole (0.5mg/L), and no antifungal (positive-con-
trol well) (Fig. 1). Plates were incubated at 35 °C and
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examined for growth at 24, 48, and 72 h. The interpret-
ation of the plates was as follows. If colonies of an Asper-
gillus spp. were observed in the control well and no
growth in azole wells of the four-well petri plate, the iso-
late was categorized as an azole-susceptible Aspergillus
spp. If colonies of Aspergillus grew on the azole wells, then
it was categorized as an azole-non-susceptible Aspergillus
spp. All the tested isolates were found to be susceptible to
the triazoles.
The minimum inhibitory concentration (MIC) of repre-
sentative isolates {A. flavus [n = 15(13.2%)], A. fumigatus
[n = 15(13.2%)], A. niger [n = 8(7.02%)] and A. terreus
[n = 3(2.6%)]} was tested according to the CLSI broth
microdilution method [19]. Briefly, 96-well U-bottom mi-
cro titer plates (Costar, Corning Incorporated) were used.
Drug dilutions were prepared following the 2-fold drug di-
lution scheme described in document M38-A2 to yield
serial 2-fold drug dilutions (from 0.03 to 16mg/L), which
were twice as concentrated as the final concentrations.
The microdilution plates were stored at − 70 °C until use.
Aspergillus conidial inoculum suspensions were prepared
as described above to an O.D. of 0.9–0.13. This sus-
pension was then diluted 1:50 times with RPMI 1640
broth to give a final inoculum density of 0.4 × 104-5 ×
104 CFU/ml in 200 μL when added to an equal vol-
ume of drug suspension in the microtiter plate well,
as confirmed by quantitative inoculum controls [19].
Growth (drug-free) and fungus-free controls were
included. The microdilution plates were incubated at
35 °C and examined for the MICs after 46 to 50 h.
The MIC was the lowest drug concentration that pre-
vented any discernible growth (100% inhibition).
Interpretation of results: Breakpoints for mold testing
have not been established by the CLSI. However, work-
ing breakpoints have been assigned as follows [19]:
Itraconazole: susceptible (MIC ≤1 mg/L), intermediate
(MIC 2mg/L) and resistant (MIC ≥4 mg/L). Voricona-
zole: susceptible (MIC ≤1 mg/L), intermediate (MIC 2
mg/L) and resistant (MIC ≥4 mg/L). Posaconazole: sus-
ceptible (MIC ≤1 mg/L), intermediate (MIC 2mg/L) and
resistant (MIC ≥4 mg/L).
American Type Culture Collection (ATCC) strains
used as controls in the susceptibility testing were Can-
dida parapsilosis ATCC 22019, Candida krusei ATCC
6258 and A. flavus ATCC 204304. The quality control
results were within acceptable quality control ranges on
all days of testing. Ethical exemption was obtained from
the institutional ethics review committee.
Sample size
Sample size was calculated using OpenEpi online soft-
ware for “Sample Size for a Proportion or Descriptive
Study” and the formula used was n = [DEFF*Np (1-p)]/
[(d2/Z21-α/2*(N-1) + p*(1-p)]. The number of patients
registered with AKUH and diagnosed with aspergillosis
(according to ICD-09), in 2015, were 49 [21]. Hence,
using this population, one hundred and fourteen non-
duplicate Aspergillus isolates were sampled to detect a
hypothesized frequency of triazole resistance of 1.7 + 1%
at 95% level of confidence [8]. Non-probability consecu-
tive sampling was used.
Results
One hundred and fourteen, clinically significant Aspergillus
isolates [A. fumigatus (38; 33.3%), A. flavus (64; 56.1%), A.
niger (9; 7.9%) and A. terreus (3; 2.6%)] were included in the
study. The clinical spectrum included invasive aspergillosis
(IA) (n = 25; 21.9%) further divided into proven invasive
extrapulmonary aspergillosis (n = 8; 7%), proven invasive
pulmonary aspergillosis (IPA) (n = 6; 5.3%), putative/prob-
able IPA (n = 11; 9.6%). Eighty nine isolates from patients
with chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%),
allergic bronchopulmonary aspergillosis (ABPA) (n = 4;
3.5%), severe asthma with fungal sensitization (SAFS) (n =
4; 3.5%) and saprophytic tracheobronchial aspergillosis
(n = 23; 20.2%) were also included.
We included samples from nine children (younger
than 18-yr-old). One had IPA with A. fumigatus (Fig. 1),
and three suffered from ABPA (A. flavus, A. fumigatus,
A. terreus) two of whom improved on itraconazole.
Three more children had SAFS (A. flavus, A. fumigatus,
A. niger). One 16-year-old girl had post-tuberculosis
Fig. 1 Aspergillus fumigatus isolate recovered from an Invasive
Pulmonary Aspergillosis patient, found susceptible to the triazoles
on agar screening. Itraconazole 4 mg/L in left quadrant, Voriconazole
1 mg/L below and on the right, Posaconazole 0.5 mg/L. Growth
control is on the top quadrant
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CPA with A. flavus. One was saprophytic tracheobron-
chial aspergillosis with A. fumigatus. The male to female
ratio of our patients was 2.0 (Table 1).
All the isolates were categorized as triazole-susceptible
based on the triazole antifungal agar screening. The MICs
of the three azole antifungals for 41 representative isolates
tested were found to be ≤1mg/L and hence according to
CLSI breakpoints, all the isolates tested were found to be
triazole-susceptible. The minimum inhibitory concentration
required to inhibit the growth of 90% organisms (MIC90)
of itraconazole, voriconazole and posaconazole of the rep-
resentative Aspergillus isolates was 1 mg/L, 1 mg/L
and 0.5 mg/L respectively (Tables 2 and 3).
Extrapulmonary IA (Table 3) cases included three A.
flavus brain abscesses, two of whom were treated with
voriconazole. One of these patients expired, while the
other had an exposure of 28 days to voriconazole before
this isolate was recovered, and was again discharged
from the hospital on it. All three of these isolates had
voriconazole MIC of 1 mg/L while itraconazole and
posaconazole MICs were < 0.5 mg/L. We also had an A.
terreus mitral valve endocarditis case (Table 3), with a
positive galactomannan assay and beta d-glucan assay
and had been started empirically on fluconazole. Unfor-
tunately, the patient was not admitted at our hospital
and was lost to follow-up after the report was finalized.
We also tested three A. flavus strains causing invasive si-
nusitis (Table 3), one of which was previously exposed
to voriconazole.
Of the 17 IPA cases for which we also determined an-
tifungal MICs (Table 3), four patients suffered from
hematological or solid organ malignancy. Voriconazole
was the most common choice of antifungal in both the
oncology and pulmonology patients, with the MIC90 of
0.95 mg/L for all Aspergillus species. There were IA in
critically ill ICU patients (n = 5, all A. flavus) with two of
them having positive galactomannan and beta d-glucan
assay. One patient received voriconazole which was a
good treatment option with an MIC of 0.5 mg/L.
Our study included 58 isolates from patients with CPA
(CNPA n = 10, CCPA n = 6, CFPA n = 13, aspergilloma
n = 5). One patient with the clinical spectrum bordering
on CCPA/CFPA and a recurrent infection with A. niger,
had received prolonged treatment with itraconazole for
197 days. Two of the CPA patients were treated with
voriconazole (MIC of both was 0.5 mg/L) while another
two received itraconazole, with one having prolonged
exposure; itraconazole MICs of both these isolates was
0.25 mg/L. Two of our ABPA patients were discharged
on itraconazole, MIC of both the isolates was 0.25 mg/L.
Five of our isolates were previously exposed to tria-
zoles, as mentioned above. Four of them were A. flavus,
out of which two were proven IA; one was a brain ab-
scess, who had an exposure of 26 days to voriconazole
(MIC voriconazole was 1 mg/L) and was discharged on
it. The other A. flavus IA was isolated from a case of re-
current sinusitis, who had an exposure of 47 days to vor-
iconazole (MIC voriconazole was 1 mg/L) and was
discharged on it. The third one was a probable IPA in a
neutropenic patient of relapsed acute myelogenous
leukemia who had an exposure of 17 days to voricona-
zole (MIC voriconazole was 1 mg/L). Unfortunately the
patient expired, unclear whether it was due to primary
disease or the fungal infection. The fourth one was a
CPA patient who was exposed to itraconazole (MIC itra-
conazole was 0.25 mg/L). This was an outpatient and
was lost to follow up and the duration of exposure could
not be ascertained. The fifth was a patient with the clin-
ical spectrum bordering on CCPA/CFPA and a recurrent
infection with A.niger, who had received prolonged
treatment with itraconazole for 197 days when the sam-
ple was submitted, and was still under treatment with it.
(MIC itraconazole was 0.25 mg/L).
Discussion
In the present study, we examined itraconazole, vorico-
nazole and posaconazole susceptibility in a spectrum of
clinically significant Aspergillus spp. A. flavus was found
to be the most common clinically significant Aspergillus
spp. in this study followed by A. fumigatus, A. niger and
A. terreus, respectively. We screened 114 isolates for
azole resistance but we could not detect any triazole re-
sistant Aspergillus isolate. MICs of representative isolates
were tested by broth microdilution and all of them were
found to be triazole susceptible. Hence, triazole
Table 1 Age and gender distribution of the Aspergillus strains
isolated from a clinical spectrum of aspergillosis
n (%) Age range (y) Gender
(M:F)
No. of isolates 114 6–90 2.0
Clinical diagnoses
Extrapulmonary 8 (7.0) 20–60 1.6
IA proven 8 (7.0) 20–60 1.6
Pulmonary 103 (90.4) 6–90 2.0
IPA proven 6 (5.3) 11–60 2.0
IPA putative/probable 11 (9.6) 22–81 1.8
CPA 58 (50.9) 16–90 1.7
ABPA 4 (3.5) 6–32 1.0
SAFS 4 (3.5) 6.5–64 1.0
Saprophytic tracheobronchial
aspergillosis
23 (20.2) 15–90 0.2
Previously triazole exposed
isolates
5 (4.4) 40–65 0.7
IA Invasive Aspergillosis, IPA Invasive Pulmonary Aspergillosis, CPA Chronic
Pulmonary Aspergillosis, ABPA Allergic Bronchopulmonary Aspergillosis, SAFS
Severe Asthma with Fungal Sensitization
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resistance could not be detected in clinical Aspergillus
isolates from a single laboratory in our country over the
last 4 years. Our data can nevertheless serve as baseline
for future surveillance of triazole susceptibility in clinic-
ally significant Aspergillus spp. in our region, as such
data in either clinical or environmental Aspergillus iso-
lates is currently lacking from Pakistan.
Resistant isolates harboring either TR34/L98H or
TR46/Y121F/T289A mutations have been found in en-
vironmental and clinical samples from several countries
including the USA, United Kingdom, Ireland, most
countries in Europe, Tanzania, and Australia [22]. Are-
ndrup et al. screened a total of 3788 Aspergillus isolates
for azole resistance from a similar clinical spectrum to
our study, but as a multicenter international surveillance
during January 2009–January 2011. A. fumigatus species
complex constituted 77.6% of their isolates, while in our
study, A. flavus was the most common species (56.1%),
and A. fumigatus was only 33.3% of the isolates. Ac-
quired azole resistance in A. fumigatus was detected in
11 of 17 European centers in nine countries, with an
overall 3.2% prevalence of azole resistance. The median
MICs of itraconazole, voriconazole and posaconazole for
the resistant isolates were > 8, 2 and 1mg/L respectively.
TR34/L98H was the predominant mechanism of resist-
ance. Our isolates showed lower MICs. The MIC90 of
Table 2 MIC range and MIC90 of triazoles of four commonly isolated Aspergillus spp. in clinically significant cases
Isolates Aspergillus flavus Aspergillus fumigatus Aspergillus niger Aspergillus terreus
Total isolates tested [n (%)] 41 (36) 15 (13.2) 15 (13.2) 8 (7) 3 (2.6)
MIC range itraconazole (mg/L) 0.06–1 0.06–1 0.25–1 0.25–1 0.25
MIC90 itraconazole (mg/L) 1 0.4 0.5 1 0.25
MIC range voriconazole (mg/L) 0.125–1 0.125–1 0.25–1 0.25–0.5 0.5–1
MIC90 voriconazole (mg/L) 1 1 1 0.5 0.9
MIC range posaconazole (mg/L) 0.06–1 0.06–1 0.25–1 0.25–0.5 0.5
MIC90 posaconazole (mg/L) 1 0.5 0.5 0.5 0.5
MIC Minimum Inhibitory Concentration, MIC90 Minimum Inhibitory Concentration to inhibit the growth of 90% organisms
Table 3 MIC range and MIC90 of triazoles of Aspergillus spp. according to the clinical spectrum
Isolates Aspergillus flavus Aspergillus fumigatus Aspergillus. niger Aspergillus terreus
Total isolates screened [n (%)] 114 64 (56.1) 38 (33.3) 9 (7.9) 3 (2.6)
Extrapulmonary IA proven [n (%)] 8 (7.0) 7 (6.1) 0 0 1 (0.9)
MIC tested [n (%)] 7 (6.1) 6 (5.3) – – 1 (0.9)
MIC Itraconazole range (mg/L) 0.25–0.5 0.25–0.5 – – 0.25
MIC Voriconazole range (mg/L) 0.5–1 0.5–1 – – 1
MIC Posaconazole range (mg/L) 0.06–0.5 0.06–0.5 – – 0.5
Invasive Pulmonary Aspergillosis (Proven, Putative/Probable) 17 (14.9) 12 (10.5) 4 (3.5) 1 (0.9) 0
MIC tested [n (%)] 9 (7.9) 4 (3.5) 4 (3.5) 1 (0.9) 0
MIC Itraconazole range (mg/L) 0.06–0.5 0.06–0.25 0.25–0.5 0.5 0
MIC Voriconazole range (mg/L) 0.5–1 0.5–1 0.5–1 0.5 0
MIC Posaconazole range (mg/L) 0.5 0.5 0.5 0.5 0
Non-Invasive Pulmonary Aspergillosis (CPA, ABPA, SAFS) 66 (57.9) 37 (32.5) 21 (18.4) 6 (5.3) 2 (1.8)
MIC tested [n (%)] 22 (19.3) 5 (4.4) 10 (8.8) 5 (4.4) 2 (1.8)
MIC Itraconazole range (mg/L) 0.25–1 0.25–1 0.25–1 0.25–1 0.25
MIC Voriconazole range (mg/L) 0.125–1 0.125–1 0.25–1 0.25–0.5 0.5
MIC Posaconazole range (mg/L) 0.25–1 0.5–1 0.25–1 0.5 0.5
Saprophytic tracheobronchial Aspergillosis [n (%)] 23 (20.2) 8 (7.0) 13 (11.4) 2 (1.8) 0
MIC tested [n (%)] 3 (2.6) – 1 (0.9) 2 (1.8) –
MIC Itraconazole range (mg/L) 0.25–1 – 0.25 0.5–1 –
MIC Voriconazole range (mg/L) 0.25–1 – 1 0.25–0.5 –
MIC Posaconazole range (mg/L) 0.25–0.5 – 0.5 0.25–0.5 –
IA Invasive Aspergillosis, CPA Chronic Pulmonary Aspergillosis, ABPA Allergic Bronchopulmonary Aspergillosis, SAFS Severe Asthma with Fungal Sensitization, MIC
Minimum Inhibitory Concentration
Moin et al. Antimicrobial Resistance and Infection Control            (2020) 9:62 Page 5 of 8
itraconazole, voriconazole and posaconazole of our A
.fumigatus isolates were 0.5, 1 and 0.5 mg/L respectively
(Table 2) [23, 24].
Data on azole resistant Aspergillus spp. from clinical
and environmental isolates is also available from Far
East: Taiwan, Thailand, Japan; and our neighboring
countries, India, China, and Iran. Tashiro et al. con-
firmed that long-term itraconazole therapy induced
azole resistance in A. fumigatus isolates with itracona-
zole MICs ≥4 mg/L is isolates that were exposed to itra-
conazole for > 115 days [24]. Five of our isolates were
previously exposed to azoles, as described above. How-
ever, we could not detect any triazole resistance in our
isolates. One of these had an exposure of 197 days to
itraconazole, but its MIC was 0.25 mg/L. Liu et al., from
China identified four azole resistant A. fumigatus strains
out of 72 clinical isolates, based on mutations of cyp51A.
Three strains were highly resistant to itraconazole (MIC
16mg/L), two of which exhibited the TR34/L98H/
S297T/F495I mutation, while one carried only the
TR34/L98H mutation. The fourth multiazaole-resistant
isolate (itaconazole 4 mg/L, voriconazole 2 mg/L) carried
a new G432A mutation [25]. Chowdhary et al. found
azole resistance in [12] 1.7% A. fumigatus clinical isolates
during 4 years in a referral Chest Hospital in Delhi,
India. These isolates harbored TR34/L98H mutation in
83.3% isolates with a pan-azole resistant phenotype,
linked to the use of fungicide azoles in agricultural prac-
tices. Of the 12 resistant A. fumigatus, 11 showed a pan-
azole resistant phenotype exhibiting high MIC of all the
triazoles, itraconazole [geometric mean (GM) MIC = 16
mg/L], voriconazole (GM MIC = 8mg/L), and posacona-
zole (GM MIC = 2.82 mg/L). In contrast, a solitary A.
fumigatus isolate exhibited high MIC (> 16mg/L) against
itraconazole only [8]. Chowdhary et al. also reported 7%
triazole resistance in A. fumigatus isolates from 24 envir-
onmental samples in India, which shared the same
TR34/L98H mutation in the cyp51 gene and showed
cross-resistance to itraconazole, voriconazole and posa-
conazole, and to six triazole fungicides used extensively
in agriculture. The mutated environmental strains
showed high MICs (itraconazole GM MIC = 16mg/L],
voriconazole (GM MIC = 8.7 mg/L), and posaconazole
(GM MIC = 1.03 mg/L), and the mutated clinical isolates
showed the following MICs (itraconazole GM MIC = 16
mg/L], voriconazole (GM MIC = 5.9 mg/L), and posaco-
nazole (GM MIC = 3.2 mg/L) [26] [26]. Nabili et al. in a
three-year study, screened 513 samples (213 clinical and
300 environmental samples) from ten provinces of Iran
for azole resistance, and found a 6.6% prevalence of azole-
resistant A. fumigatus in Iran ([clinical and environmental
A. fumigatus isolates with decreased drug susceptibility
and mutations: itraconazole MIC range 4 to > 16mg/L,
voriconazole MIC range 0.25 to > 16mg /L posaconazole
MIC range 0.016 to 4mg/L]. Among resistant isolates,
TR34/L98H mutations in the CYP51A gene were the most
prevalent (80%) [27]. In comparison to these studies, our
isolates showed comparatively lower MICs.
J.F. Meis and, A. Chowdhary et al. recently sequenced
and analysed 24 genomes of A. fumigatus from across
the world. These isolates were rationally chosen to in-
clude an informative selection of clinical and environ-
mental isolates that were wild-type, or known to carry
the TR34/L98H allele. This population genomic analysis
showed that A. fumigatus was broadly panmictic, with as
much genetic diversity found within a country as is
found between continents [28].
The occurrence of azoles resistant isolates of A. fumiga-
tus varies worldwide, from 2.1–20% in the UK, 10–12% in
the Europe, 10% in Asia, Africa, America and Australia to
1.75% in India, probably due to varying usage of azole fun-
gicides that may select for resistance [29].
Amongst our isolates, A. flavus was the most common
one. At present, the development of azole resistance is
mainly associated with A. fumigatus and less so with A.
flavus and A. terreus; however, further surveillance is
warranted. A. flavus is the cause of a broad spectrum of
human diseases predominantly in Asia, the Middle East,
and Africa possibly due to its ability to survive better in
hot and arid climatic conditions compared to other As-
pergillus spp. [30]. In a collection of 590 clinical isolates,
from five centers in USA and Europe, the rate of vorico-
nazole resistance in A. flavus was estimated at ~ 2%
using an ECV of > 1 μg/mL [31].
There is limited data from Pakistan on the mold anti-
fungal surveillance. A study was conducted in the
Armed Forces Institute of Pathology, Rawalpindi from
January through December, 2016. 110 isolates; 45
(40.9%) A. fumigatus, 40 (36.3%) Alternaria alternata,
and 25 (22.7%) Cladosporium sphaerospermum were
tested against amphotericin B, fluconazole and voricona-
zole by broth microdilution method. The overall vorico-
nazole and amphotericin B susceptibility rates were 82.2
and 84.5%, respectively. Voriconazole resistance was
seen in only 1 (2.5%) A. fumigatus isolate, which was not
confirmed by genotyping [32]. Due to our limited re-
sources, our study also lacks the detection of molecular
mechanisms of azole resistance in our clinical isolates.
The limitations of our study are the small sample
size, and single centre which couldn’t find any tri-
azole resistant Aspergillus isolate. However, we feel
the bench experience will help introduce the screen-
ing and MICs into routine clinical practice, though
Azole resistant Aspergillus disease is a rare entity and
difficult to diagnose [10]. Unfortunately, the suscepti-
bilities could not be performed in real-time but in
batches, due to logistic issues which reduced the clin-
ical utility for some patients.
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Future directions necessitate surveillance of our envir-
onmental and clinical isolates, to determine any rising
MICs, and change in our local epidemiology. This MIC
data should be linked to clinical antifungal usage and
therapeutic drug monitoring in patients who are on
long-term azole therapy, as in CPA cases. Another con-
cern is the missing data on the quantity and the types of
antifungals used in agriculture, as Pakistan is an agricul-
tural economy and there is high risk of excessive use.
Conclusion
Triazole resistance could not be detected amongst clin-
ical Aspergillus isolates from the South of Pakistan.
However, environmental strains remain to be tested for
a holistic assessment of the situation. Thus this study
sets precedence for future periodic antifungal resistance
surveillance studies in our region on Aspergillus isolates
causing invasive disease, as well as other syndromes re-
quiring long term antifungal therapy.
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